Jörg Cammenga

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 4

Top Topics

Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Practice

Top Venues

Genesis (New York, N.Y. : 2000)

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Panagiotis Baliakas, Bianca Tesi, Jörg Cammenga, Asbjørg Stray-Pedersen, Kirsi Jahnukainen, Mette Klarskov Andersen, Helena Ågerstam, Maria Creignou, Ingunn Dybedal, Klas Raaschou-Jensen, Kirsten Grønbaek, Outi Kilpivaara, Eva Hellström Lindberg, Ulla Waitiovaara-Kautto
How to manage patients with germline DDX41 variants: Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms. HemaSphere 8 (8) (2024)
Panagiotis Baliakas, Bianca Tesi, Jörg Cammenga, Asbjørg Stray-Pedersen, Kirsi Jahnukainen, Mette Klarskov Andersen, Helena Ågerstam, Maria Creignou, Ingunn Dybedal, Klas Raaschou-Jensen, Kirsten Grønbaek, Outi Kilpivaara, Eva Hellström Lindberg, Ulla Waitiovaara-Kautto
How to manage patients with germline DDX41 variants: Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms. HemaSphere 8 (8) (2024)
Aldana Rosso, Gunnar Juliusson, Fryderyk Lorenz, Sören Lehmann, Åsa Derolf, Stefan Deneberg, Martin Jädersten, Petar Antunovic, Jörg Cammenga, Lars Möllgård, Lovisa Wennström, Emma Ölander, Mats Ehinger, Linda Fogelstrand, Martin Höglund, Vladimir Lj Lazarevic
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study. Leukemia & lymphoma 62 (8) (2021)
Javier Martin Gonzalez, Aurélie Baudet, Sahar Abelechian, Kasper Bonderup, Teresa d'Altri, Bo Porse, Cord Brakebusch, Gunnar Juliusson, Jörg Cammenga
A new genetic tool to improve immune-compromised mouse models: Derivation and CRISPR/Cas9-mediated targeting of NRG embryonic stem cell lines. Genesis (New York, N.Y. : 2000) 56 (9) (2019)